CD19 CAR T细胞治疗原发性纵隔大B细胞淋巴瘤:一项CIBMTR分析
该研究回顾性分析CIBMTR注册数据中135例接受CD19 CAR T细胞治疗的PMBCL成人患者,来自66个中心,中位年龄32岁。最佳总缓解率和完全缓解率分别为79%和67.7%,2年无进展生存率和总生存率分别为58.6%和80.8%。既往ICI暴露与较低的2年累积复发率和较高的2年非复发死亡率相关,但无进展生存和总生存无显著差异。
要点
- CD19 CAR T细胞治疗在PMBCL中产生高缓解率:最佳总缓解率79%、完全缓解率67.7%。
- 2年无进展生存率58.6%、总生存率80.8%,2年累积复发率36%、非复发死亡率5.4%。
- 既往ICI暴露者2年累积复发率较低(21.7% vs 41.6%,p=0.03),但2年非复发死亡率较高(11.7% vs 2.8%,p=0.03)。
核心结论
- CD19 CAR T细胞治疗在PMBCL患者中产生高比例的持久缓解,且严重毒性发生率低。
研究设计与样本
- 回顾性分析CIBMTR注册数据,纳入135例接受标准治疗CD19 CAR T细胞治疗的PMBCL成人患者,来自66个中心。
主要发现
- CAR T细胞治疗时中位年龄32岁,39例(28.9%)既往接受过ICI治疗。
- 最佳总缓解率和完全缓解率分别为79%和67.7%。
- 2年无进展生存率为58.6%(95% CI,49.7-67.3),2年总生存率为80.8%(95% CI,72.6-87.8)。
- 2年累积复发率为36%(95% CI,27.8-44.7),2年非复发死亡率为5.4%(95% CI,1.9-10.5)。
- ≥3级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征发生率分别为6.1%和14.7%。
关键数值与推荐
- 既往ICI暴露者2年累积复发率为21.7%,未暴露者为41.6%(p=0.03)。
- 既往ICI暴露者2年非复发死亡率为11.7%,未暴露者为2.8%(p=0.03)。
- 既往ICI暴露与未暴露者之间无进展生存无统计学差异(p=0.19),总生存无统计学差异(p=0.26)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cells engineered with CD19-directed chimeric antigen receptors (CD19 CAR) T cells have become standard treatment for patients with high risk, relapsed or refractory (R/R) large B-cell lymphomas (LBCL). However, outcomes in patients with rare subsets of LBCL, such as primary mediastinal large B-cell lymphoma (PBMCL), have not been well characterized. The impact of prior immune checkpoint inhibitor (ICI) treatment, commonly used to treat R/R PMBCL, is also unknown. To address these gaps, we retrospectively analyzed CIBMTR registry data including PMBCL patients undergoing CD19 CAR T-cell therapy per standard-of-care. A total of 135 PMBCL adults from 66 centers were included. Median age at the time of CAR T-cell therapy was 32. Thirty-nine patients (28.9%) had received an ICI prior to CAR T-cell therapy. The best overall and complete response (CR) rates after CD19 CAR T-cell therapy were 79% and 67.7%, respectively. The 2-year progression-free (PFS) and overall survival (OS) were 58.6% (95% CI, 49.7-67.3) and 80.8% (95% CI, 72.6-87.8), respectively. The 2-year cumulative incidence (CI) of relapse and non-relapse mortality (NRM) were 36% (95% CI, 27.8-44.7) and 5.4% (95% CI, 1.9-10.5), respectively. We observed grade ≥ 3 CRS and ICANS in 6.1% and 14.7%, respectively. Prior ICI exposure was associated with lower 2-year CI of relapse (ICI-exposed, 21.7%; ICI-naïve, 41.6%; p = 0.03) and higher 2-year NRM (ICI-exposed, 11.7%; ICI-naïve, 2.8%; p = 0.03). We could not confirm statistically different PFS (p = 0.19) or OS (p = 0.26) between ICI-exposed and ICI-naïve patients. CD19 CAR T-cell therapy led to high rates of durable responses in PMBCL patients with low rates of severe toxicities.
引用
- Gauthier J, Ahn KW, Patel J, et al. CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis. Am J Hematol. 2025. PMID: 40785644. doi:10.1002/ajh.70033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。